AstraZeneca’s BAXFENDY™ (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive ...
The FDA approved the aldosterone synthase inhibitor Baxfendy (baxdrostat) for adults with inadequately controlled hypertension.
A new blood pressure medication has been approved in the U.S., but this one isn’t quite like others that help treat ...
When you think of high blood pressure, lifestyle choices around nutrition or exercise may come to mind—not your hormones. But ...
Zacks Investment Research on MSN
AstraZeneca gets FDA nod for new hypertension drug Baxfendy
AstraZeneca AZN announced that the FDA has approved baxdrostat for treating adult patients with uncontrolled or ...
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has secured US approval for Baxfendy, the first in a new class of blood pressure ...
Oral presentation highlights efficacy and safety profile of lorundrostat in patients with uncontrolled hypertension and chronic kidney disease ...
The FDA approved the first-in-class oral aldosterone synthase inhibitor baxdrostat (Baxfendy) to treat adults with ...
New drug Baxdrostat lowers stubborn high blood pressure in difficult-to-treat patients, showing promising results in a global ...
A steroid hormone called aldosterone is linked to an increased risk of kidney failure in patients with chronic kidney disease (CKD), according to a study published in the European Heart Journal today ...
Please provide your email address to receive an email when new articles are posted on . Aldosterone is associated with an increased risk of chronic kidney disease progression and the development of ...
A drug that has been used to slow progression of kidney and cardiovascular disease in people with type 2 diabetes may also help people with chronic kidney disease who do not have diabetes, according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results